Clinical Trial Update: Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 trial of ganitumab in locally advanced unresectable pancreatic cancer has been terminated; results were posted on 2024-11-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Ganitumab (ganitumab)

Snippet

Sponsor: NantBioScience, Inc. | Conditions: Adenocarcinoma of the Pancreas, Locally Advanced | Phase 2 | Status: TERMINATED | Results posted: 2024-11-08